User profiles for P. Bossi
Paolo BossiAssociate Professor of Medical Oncology, University of Brescia Verified email at unibs.it Cited by 12829 |
[HTML][HTML] The spectrum of malnutrition/cachexia/sarcopenia in oncology according to different cancer types and settings: a narrative review
P Bossi, P Delrio, A Mascheroni, M Zanetti - Nutrients, 2021 - mdpi.com
Nutritional status in oncological patients may differ according to several modifiable and non-modifiable
factors. Knowledge of the epidemiology of malnutrition/cachexia/sarcopenia may …
factors. Knowledge of the epidemiology of malnutrition/cachexia/sarcopenia may …
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
Background Mucositis is a significant toxicity of cancer therapy with numerous systemic
sequelae. The goal of this systematic review was to update the Multinational Association of …
sequelae. The goal of this systematic review was to update the Multinational Association of …
[HTML][HTML] Digital health for optimal supportive care in oncology: benefits, limits, and future perspectives
Background Digital health provides solutions that capture patient-reported outcomes (PROs)
and allows symptom monitoring and patient management. Digital therapeutics is the …
and allows symptom monitoring and patient management. Digital therapeutics is the …
Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines
Purpose To systematically review the literature and update the evidence-based clinical
practice guidelines for the use of photobiomodulation (PBM), such as laser and other light …
practice guidelines for the use of photobiomodulation (PBM), such as laser and other light …
Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study
LD Locati, P Bossi, F Perrone, P Potepan, F Crippa… - Oral oncology, 2009 - Elsevier
EGFR overexpression in salivary gland carcinomas provides the rational for the
investigation of anti-EGFR treatments in recurrent and/or metastatic salivary gland cancers (RMSGCs). …
investigation of anti-EGFR treatments in recurrent and/or metastatic salivary gland cancers (RMSGCs). …
Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
P Bossi, AT Chan, L Licitra, A Trama… - Annals of …, 2021 - annalsofoncology.org
Nasopharyngeal carcinoma (NPC) is a disease with unique epidemiological features. The
distribution of the disease demonstrates a clear regional, racial and gender prevalence. In …
distribution of the disease demonstrates a clear regional, racial and gender prevalence. In …
[HTML][HTML] Global cancer control: responding to the growing burden, rising costs and inequalities in access
The cancer burden is rising globally, exerting significant strain on populations and health
systems at all income levels. In May 2017, world governments made a commitment to further …
systems at all income levels. In May 2017, world governments made a commitment to further …
Angiogenesis in colorectal tumors: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations
P Bossi, G Viale, AKC Lee, RM Alfano, G Coggi… - Cancer research, 1995 - AACR
Angiogenesis is a crucial step in tumor growth and progression. Its quantitation by
microvessel counting is of prognostic value in several types of malignancies. Scarce data are …
microvessel counting is of prognostic value in several types of malignancies. Scarce data are …
[HTML][HTML] Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients
…, JB Epstein, S Elad, J Allemano, P Bossi… - Supportive Care in …, 2013 - Springer
Purpose The aim of this project was to develop clinical practice guidelines on the use of
antimicrobials, mucosal coating agents, anesthetics, and analgesics for the prevention and …
antimicrobials, mucosal coating agents, anesthetics, and analgesics for the prevention and …
[HTML][HTML] Vitamin D and SARS-CoV2 infection, severity and mortality: A systematic review and meta-analysis
… All reported p values were two sided and p<0.05 was considered statistically significant. …
regular doses and those involving high doses (p = 0.18; p = 0.28, respectively for the ones with …
regular doses and those involving high doses (p = 0.18; p = 0.28, respectively for the ones with …